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Lymph node development depends on well-orchestrated interactions between lymphoid tissue inducer cells
and stromal cells. In this issue of Immunity, Pikor and colleagues (2015) find that signals from IL-17-producing
T helper cells can alter the stromal microenvironment of the inflamed brain to generate a neo-lymphoid organ
that drives further inflammation.Secondary lymphoid tissues (SLTs), i.e.,
lymph nodes (LNs) and spleen, are highly
organized organs with dedicated areas
for the encounter between antigens
(Ags) and Ag-presenting cells, as well as
B and T cells, providing an ideal environ-
ment for the initiation of adaptive immune
responses (Hofmann et al., 2010). SLTs
arise during embryonic development
at well-defined sites, usually between
lymphatic ducts and blood vessels. The
activity of lymphoid tissue inducer (LTi)
cells, a subset of innate lymphoid cells
(ILCs) that depend on the transcription
factor RORgt, is crucial for initiating SLT
formation. During embryonic develop-
ment, LTi cells initiate the formation of
SLT anlagen (site of SLT initiation) through
interactions with stromal lymphoid tissue
organizer (LTO) cells. Although lympho-
toxin b receptor (LTbR) engagement is
not absolutely necessary for the initial
wave of LTi cell recruitment to the LN an-
lage, it seems to be required for the matu-
ration and homeostasis of stromal cells
(Chai et al., 2013). Activated LTOs then
produce a number of factors including
adhesion molecules and chemokines,
which attract B and T lymphocytes. The
stromal cells in these early LNs can then
develop into either follicular dendritic cells
(FDCs) or fibroblast reticular cells (FRCs),
which provide the molecular and struc-
tural support for the attraction of B and
T cells, respectively. The complex organi-
zation and genesis of SLTs highlight the
interactions among hematopoietic cells,
stromal cells, adhesion molecules, and
cytokines.
In contrast to SLTs, tertiary lymphoid
tissues (TLTs) can arise in chronically in-
flamed tissues, for instance, during auto-
immune and/or inflammatory diseases(Neyt et al., 2012). The defining features
of TLTs are juxtaposed B and T cell areas
with FDC and FRC networks in each
respective zone, along with high endothe-
lial venules (HEVs) andgerminal center ac-
tivity in the B cell areas (i.e., class switch-
ing). There is evidence that TLTs can thus
provide LN-like support for immune re-
sponses directly within the inflamed tissue
microenvironment. In particular, in the in-
flamed CNS, during multiple sclerosis
(MS), for instance, TLT formation is well
described, but the functional impact on
disease development is a matter of spec-
ulation. There are numerous open ques-
tions regarding the development and
function of these structures: (1) what are
the cellular players involved in the forma-
tion of TLTs in the adult, (2) what are the
molecular underpinnings of this complex
neo-organogenesis, and (3) what is the
impact of TLTs on disease?
These questions most likely motivated
Pikor and colleagues (2015) to delve
deeper into studying the role of interleukin
17 (IL-17)-producing T helper (Th) cells
in TLT formation. In agreement with an
earlier report (Peters et al., 2011), they
found that IL-17-secreting CNS-Ag-reac-
tive, pathogenic Th cells were capable of
inducing the formation of TLT-like struc-
tures in the inflamed brain of mice with
experimental autoimmune encephalomy-
elitis (EAE), the animal model for MS. Ex-
tending this observation, Pikor et al. found
that IL-17 and IL-22 were directly capable
of engaging fibroblastic stromal cells and
smooth muscle cells in the meninges
(a three-layered membrane protecting
the CNS) and that these cytokines were
capable of inducing the transformation
toward an FRC-like phenotype in these
meningeal stromal cells (Figure 1). ThisImmunity 43, Dealso indicates that TLT formation in the
brain is not dependent on adult LTi cells,
whose biological functions are still poorly
understood.
It has become clear that the expression
of IL-17 in Th cells is notmaintained in vivo
and that these cells generally revert
to secreting type I cytokines (Kurschus
et al., 2010). Also, mice lacking the genes
encoding IL-17A and IL-22 can still
develop EAE and other autoimmune dis-
eases. Lastly, whereas IL-17 has previ-
ously been implicated in the formation of
TLTs, inducible bronchus-associated
lymphoid tissues (iBALTs), which are ca-
nonical TLTs associated with the lung,
can develop completely independently
of IL-17A and IL-17F (Fleige et al., 2012),
suggesting that these cytokines might
be sufficient but not necessary for the
generation of TLTs. Hence, it would have
been an interesting addition to the report
of Pikor et al. if they had determined
whether the adoptive transfer of Th1-
polarized encephalitogenic T cells could
also trigger the remodeling of the menin-
geal microenvironment. Importantly, the
report by Pikor et al. raises the question
of whether tissue remodeling per se might
be the primary function of IL-17 and IL-22
during neuro-inflammation. Are IL-17 and
IL-22 essentially engaging with those
CNS stromal cells, which, in contrast to
most leukocytes, constitutively express
IL-17 and IL-22 receptors?
Among the alterations observed in the
inflamed meninges was the induction of
extracellular matrix molecules (e.g., fibro-
nectin), as well as the upregulation of
chemokines (e.g., CXCL1) and adhesion
molecules (e.g., ICAM1), which could
potentially serve to trap leukocytes in the
inflamed site. Interestingly, CXCL1 hascember 15, 2015 ª2015 Elsevier Inc. 1033
Figure 1. T-Helper-Cell-Induced Lymphoid Tissue Formation in the Brain
Accumulation of IL-17 and IL-22 in the meninges stimulates remodeling of meningeal stromal cells
(fibroblasts and smoothmuscle cells) so they develop into FRCs. LTbR engagement aids the development
of FDC precursor cells, which supports B cell accumulation in the TLT. Activated FRCs in turn capture
T cells and maintain their polarization and activation.
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tioning of oligodendrocyte precursor cells
(Tsai et al., 2002) and wound healing. This
raises the possibility that the transient
production of IL-17 by CNS-invading Th
cells could also serve to induce tissue
remodeling and remyelination in general
and not only in the attraction of leukocytes
into the meningeal TLTs.
With respect to themolecular underpin-
nings of this neo-lymphoid organogen-
esis, the authors found that the FRC-like
network could be induced independently
of LTbR signaling and that IL-17 and/or
IL-22 treatment of meningeal fibroblasts
alone was sufficient to induce phenotypic
changes akin to what would be observed
in a bona fide TLT. Neutralization of this
pathway primarily affected B cell zones
in meningeal TLTs. Although the authors
failed to detect mature FDCs in the
meninges of mice with EAE, FDC forma-
tion (Krautler et al., 2012) seems more
dependent than FRC formation (Chai1034 Immunity 43, December 15, 2015 ª201et al., 2013) on LTbR signaling. The reli-
ance of B cells on LTbR signaling in the
tissue stroma confirms that mammalian
B cell maturation requires the organized
structures provided by mature SLTs or
TLTs (whereas T cells are much more
structure independent) and that produc-
tive T cell priming can occur outside of
dedicated LNs or TLTs (Hofmann et al.,
2010).
The major remaining question is
whether emerging TLTs matter in the in-
flamed brain. In other words, will the
targeted disruption of TLTs affect the
overall inflammation or even clinical dis-
ease development? Alymphoplastic
mutant mice, which are defective in
LTbR signaling and thus devoid of all
LNs, do develop EAE (Greter et al.,
2009), indicating that (1) T cell priming
against self-Ag can occur outside of dedi-
cated lymphoid structures and (2) even if
TLTs can emerge during inflammation,
their function must be largely redundant.5 Elsevier Inc.Pikor et al. propose that TLTs provide
support for the maintenance of the IL-17
expression of Th cells locally by produc-
ing polarizing cytokines such as TGFb
and IL-6 (Figure 1). It is thus tempting
to speculate that TLT formation in the
meninges in chronic inflammatory dis-
ease serves primarily in the perpetuation
of the inflammatory cascade and thus
fuels the disease. However, the verdict
on that is still outstanding. It is conversely
possible that TLTs in the inflamed CNS
serve to regulate and dampen an immune
response akin to what is observed in tu-
mormicroenvironments, where regulatory
T cells can gather to blunt T cell re-
sponses. Also, as mentioned earlier, TLT
formationmight be a sign of general tissue
remodeling and wound healing. Although
we have gained much better insights
into the formation of TLTs in chronic
inflammation, whether these are struc-
tures are good, bad, or merely pretty re-
mains to be established.
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